Search
Now showing items 1-2 of 2
Examining the therapeutic potential of the investigational agent, 15dPMJ2, in mismatch repair proficient colon cancer
(East Carolina University, 2022-08-15)
Despite the success of immune checkpoint inhibitor (ICI) therapy in many cancers, colon cancer with low microsatellite instability (MSI-L), also known as proficient mismatch repair (pMMR), does not respond to these agents. ...
Examining the therapeutic potential of the investigational agent, 15dPMJ2, in mismatch repair proficient colon cancer
(East Carolina University, 2022-08-15)
Despite the success of immune checkpoint inhibitor (ICI) therapy in many cancers, colon cancer with low microsatellite instability (MSI-L), also known as proficient mismatch repair (pMMR), does not respond to these agents. ...